You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
誠達藥業(301201.SZ):主營業務涵蓋為跨國製藥企業及醫藥研發機構提供關鍵醫藥中間體、原料藥CDMO研發生產服務
格隆匯 05-14 16:13

格隆匯5月14日丨誠達藥業(301201.SZ)在投資者互動平台表示,公司主營業務涵蓋為跨國製藥企業及醫藥研發機構提供關鍵醫藥中間體、原料藥CDMO研發生產服務,以及左旋肉鹼系列產品、仿製藥原料藥的研發、生產和銷售。同時公司在2023年底投資設立了上海誠玖泰生物醫藥有限公司,2024年一季度,其與美國Chiron Pharma, Inc.簽署了技術實施許可、轉讓、合作開發合同,雙方就幹細胞治療心梗開通後心衰適應症項目(以下簡稱“心梗項目”)、治療腦梗後亞急性期後遺症適應症項目(以下簡稱“腦梗項目”)達成技術共享合作。上述2個項目已獲得美國FDA臨牀批件,其中心梗項目已完成1期臨牀,現已進入2期臨牀研究,腦梗項目已進入1/2a期臨牀,該項目標的可實施區域為中國區域(含中國大陸、香港地區、澳門地區,不含中國台灣地區)。誠玖泰購買了位於上海市奉賢區的臨港智造園十一期項目15號廠房,該廠房建築面積5,910.6平方米,後續將用於開展幹細胞項目。公司堅持“自主創新”與“吸收引進前沿科學成果”雙管齊下,儲備了水溶性小分子氨基酸分離和純化、手性合成、過渡金屬催化、多取代雜環合成、酶催化、管道與連續流化學、分子蒸餾和精餾純化等多項核心關鍵技術,並致力於將其應用於各產品的工藝開發及生產過程中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account